Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Macuvite
- Development stage
- Unknown
- Lead developer
- Denver Farma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Macuvite is an oral dietary supplement developed by Denver Farma, formulated based on the AREDS2 (Age-Related Eye Disease Study 2) guidelines to support ocular health. It is a fixed-dose combination containing vitamin C, vitamin E, lutein, zeaxanthin, zinc, and copper. Macuvite is indicated to reduce the risk of progression of age-related macular degeneration (AMD), prevent retinal diseases associated with oxidative stress, and protect against the loss of central vision. It is formulated as gluten-free softgel capsules.
- Brand names
- Macuvite
Beyond the preview
Go deeper on Macuvite.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Macuvite.